Viridian Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Viridian Therapeutics, Inc. on July 26, 2021. The filing discloses the appointment of a new senior executive and the terms of the associated employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
On July 26, 2021, the Company appointed Kristian Humer as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Humer will also serve as the Principal Financial Officer and Principal Accounting Officer.
Management Commentary and Employment Terms
Mr. Humer's employment agreement includes the following compensation components:
- Base Salary: $530,000 annually.
- Sign-on Bonus: $400,000.
- Target Bonus: 45% of Base Salary, guaranteed for 2021 (pro-rated) and 2022.
- Equity Grant: Initial time-based option to purchase 360,000 shares of common stock, issued outside the stockholder-approved Equity Incentive Plan.
- Future Equity: Eligibility for an additional time-based option grant on or about December 31, 2021, contingent on an equity offering.
Termination Provisions: In the event of Involuntary Termination (without cause, good reason, death, or disability), Mr. Humer is entitled to 12 months of Base Salary, 12 months of accelerated vesting for Options, and up to 12 months of COBRA reimbursement. In the event of Involuntary Termination within one month before or 12 months after a change in control, the Options will be deemed fully vested.
Investor Verification Checklist
- Verify the impact of the $400,000 sign-on bonus and guaranteed bonuses on the Company's immediate cash burn rate.
- Confirm the dilution impact of the 360,000 share option grant issued outside the existing equity plan.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Monitor the Company's progress toward the equity offering required for the additional December 2021 equity grant.